Subcutaneous panniculitis-like T-cell lymphoma
ICD-10 C86.3 · ICD-11 2B00&XH3NV1

Treatment of Subcutaneous Panniculitis-like T-cell Lymphoma Without HLH and Low Tumor Burden

This protocol covers patients with subcutaneous panniculitis-like T-cell lymphoma (SPTCL) who present without hemophagocytic lymphohistiocytosis (HLH) and have low tumor burden — localized or limited subcutaneous disease.

Clinical Scenario

SPTCL without HLH and low tumor burden is a distinct management situation. Unlike HLH-associated SPTCL, where chemotherapy may be considered, patients without HLH are candidates for immunomodulatory approaches rather than cytotoxic regimens.

Treatment Approach (partial overview)

Management may involve retreatment strategies — returning to a prior approach or switching to a different regimen — with further options available for patients who have progressed through multiple prior lines of therapy. The full regimen selection, sequencing, and criteria are detailed in the complete protocol.

Instant Access to Structured Evidence-Based Regimens

References

  1. SPTCL Without HLH and Low Tumor Burden (Localized or Limited Subcutaneous Disease)
  2. While chemotherapy may be considered for patients presenting with HLH, immunomodulatory therapies are considered for patients who present without HLH.
  3. Retreatment with the same regimen used previously or an alternate regimen not used in first-line therapy may be considered to prevent disease progression.
  4. However, relapse or refractory disease after multiple previous therapies may occur, which may warrant a patient enrolling in a clinical trial, or consideration of an alternate regimen not previously used, such as in SPTCL with HLH, systemic disease, or high tumor burden.
View source ↗